The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

ERS Genomics ('ERS'), which was established to provide broad access to the foundational CRISPR/Cas9 intellectual property developed by Prof. Emmanuelle ...

A research team at the University of Cologne has made a significant breakthrough in understanding the role of the tau protein ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

A vast search of natural diversity has led scientists at MIT's McGovern Institute and the Broad Institute of MIT and Harvard ...

A team of researchers from the University of Cologne has made an important contribution to understanding the role of the tau ...

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Human stem cells reveal new insights into Alzheimer's, unlocking potential breakthroughs in understanding and treating the ...